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Sirs:
Transcatheter pulmonary valve implantation was ﬁrst per-
formed in 2000 by Philip Bonhoeffer [1]. As a generally
available product (Melody Valve, Medtronic, Minneapolis,
MN, USA), the valve was introduced in clinical practise in
summer 2007. Since then about 1,500 valves have been
implanted worldwide. One of the drawbacks of the Melody
valve, however, is its maximal diameter of 22 mm. Parallel
to this development, the Edwards SAPIEN aortic valve was
evaluated to be implanted into pulmonary position in a
small series of patients [2]. Since May 2010 this valve is
certiﬁed and commercially available in sizes of 23 and
26 mm diameter as an implant for the pulmonary artery
(Edwards Sapien Pulmonic THV, Edwards Lifesciences,
Irvine, CA, USA) [3]. We report on the ﬁrst implantation of
this CE-marked valve in Europe.
A 72-year-old woman received a Ross-procedure in
2007 due to a severe combined aortic valve dysfunction. In
pulmonary position a decellularized porcine valve (Matrix
P, AutoTissue GmbH, Berlin, Germany) was implanted in
another institution. Three years after the index operation,
this biological valve degenerated and there was severe
pulmonary insufﬁciency with a regurgitation fraction of
60% and marked right ventricular dilatation measured by
MRI. The patient had noted a decline in exercise tolerance
for 6 months with NYHA-class III symptoms. She suffered
from chronic atrial ﬁbrillation and had a left ventricular
ejection fraction of 45% with excellent autograft function.
In a diagnostic catheterization, coronary atherosclerosis
was excluded and the pulmonary regurgitation conﬁrmed.
Right ventricular systolic pressure was 43 mmHg with a
mildgradientatthedistalanastomosisofthebioprosthesisto
the pulmonary bifurcation of 10 mmHg. Angiography
revealed large diameters of 22–26 mm at the level of the
valve. Only at the distal anastomosis, a discrete reduction to
19 mm diameter could be found (Fig. 1a, b). Because no
calciﬁcation of the valve was present, a sizing manoeuvre
was performed with a compliant balloon (AGA Medical,
Golden Valley, MN, USA). A minimal diameter of 22 mm
could be found. Simultaneously, a coronary injection ruled
out any coronary artery near the implantation site (Fig. 1b).
Tocreatearigidlandingzoneforthetranscathetervalve,the
anastomosis was pre-stented: A 48 mm XXL Andrastent
(AndramedGmbH,Reutlingen,Germany)wasimplantedon
a24 mmBiB-Balloon(NuMEDInc.,Hopkinton,NY,USA)
and ﬂared at its distal end with a 16 mm Z-Med-Balloon
(NuMED Inc., Hopkinton, NY, USA) inﬂated simulta-
neouslywiththeBiB.Then,two45 mmCP-Stents(onebare
metal, one covered, NuMED Inc., Hopkinton, NY, USA)
were subsequently implanted with the same 24 mm balloon
into the target region (Fig. 1c). A 26 mm transcatheter
pulmonary valve was implanted (Edwards Sapien Pulmonic
THV, Edwards Lifesciences, Irvine, CA, USA) through a
24 F sheath (outer diameter 28 F) without any problem
(Fig. 1d). The valve was angiographically conﬁrmed to be
symmetrically conﬁgured and competent without any
residual pressure gradient. The right ventricular systolic
pressure at the end of the procedure was 30/0–5 mmHg.
Fluoroscopy time was 17.2 min.
The introduction of transcatheter pulmonary valves into
clinical practice has broadened the interventional
P. Ewert (&)  F. Berger
Department of Congenital Heart Diseases,
German Heart Institute, Augustenburger Platz 1,
13353 Berlin, Germany
e-mail: ewert@dhzb.de
E. Horlick
Toronto General Hospital, Toronto, Canada
123
Clin Res Cardiol (2011) 100:85–87
DOI 10.1007/s00392-010-0214-ypossibilities in congenital heart diseases and in patients after
the Ross-procedure [4, 5]. Both commercially available
valves are mounted on balloon expandable stents. Thus, the
needofarigidtargetzonetosafelyanchorthevalve-carrying
stent is mandatory in order to prevent valve dislocation. The
Melody valve from Medtronic is an original bovine jugular
vein prepared in toto for implantation in man. The valve
functions in low pressure conditions and is extremely for-
giving with regard to smaller diameters and asymmetry, i.e.
the same valve works perfectly well in a range from at least
14 mm up to 22 mm diameter as well as in oval conﬁgura-
tions. The Sapien pulmonic valve from Edwards Lifesci-
ences is a bovine pericardial valve which comes in two
differentsizesof23and26 mmdiameter.Itworksbestatthe
nominal size and tolerates only minor deviations in size and
symmetry. Smaller deployment sizes have not yet been
tested. In this sense, these products could be used to
complement each other. If smaller valve diameters are
appropriate, the Melody valve could be used up to 22 mm
diameter (introducer size 22 F outer diameter), for larger
diameters up to 26 mm the SAPIEN pulmonic valve (intro-
ducer size up to 28 F outer diameter) is available (Fig. 2).
In contrast to the transcatheter implantation of an aortic
valve, it is noteworthy that transcatheter pulmonary valves
need a landing zone usually prepared by pre-stenting. Thus,
the transcatheter implantation of a valve in the pulmonary
position is a complex procedure. Often, the most chal-
lenging part is not the implantation of the valve itself, but
the preparation of the landing zone. The meticulous
exclusion of any possible coronary impingement by the
implantation of the stents, and the awareness of possible
conduit ruptures are possibly the two major factors to have
been considered during the procedure. A variety of large
balloon expandable stents (bare metal and covered), large
balloons, sheaths and bail out equipment as well as expe-
rience in the use of this equipment are prerequisites to
perform a transcatheter pulmonary valve implantation
successfully and safely. Due to the relatively small number
of cases, we would recommend to perform the procedure
only in larger centres with at least 15 transcatheter
pulmonary valve implantations per year.
Fig. 1 a Right ventricular angiography: large outﬂow tract, no valve
leaﬂets, mild narrowing at distal anastomosis of a Matrix P valve.
b Balloon sizing of the landing zone: simultaneous angiography of the
left coronary artery. The balloon does not impinge on the coronary
artery. The mild indentation in the balloon measures 20 mm in
diameter. c Two large stents are already in place, a third one is about
to be implanted to prepare a rigid landing zone for the valve.
d Implantation of the SAPIEN pulmonic valve in the pre-stented
pulmonary artery
Fig. 2 Final angiography after implantation of three large stents and
a 26 mm SAPIEN pulmonic valve. There is no residual gradient and
no pulmonary regurgitation. The valve is expanded completely
and symmetrically (small picture in lower left corner)
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